Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Bank of America enters its October 14 quarterly print with a bruising month behind it and a line of analysts quietly marking down their targets, even as most refuse to cut their ratings.
The price tells the starkest part of the story. BAC closed at $53.52 on Wednesday, down nearly 15% over the past month and off 1.7% on the week. That selloff is not unique to BAC: most of its large-bank peers have pulled back, with USB falling 2.8% on the week, PNC down 2%, and WFC roughly flat. But BAC's one-month drawdown is sharper than most, and the earnings clock is now ticking with six days to go.
The Street's response to the slide has been to nudge targets lower while holding the line on ratings. UBS trimmed its target from $70 to $67 this week while keeping its Buy. JP Morgan cut from $68 to $62, maintaining Overweight. Evercore ISI and Truist both did the same, shaving targets while preserving positive ratings. TD Cowen reinstated with a Hold at $60 on Thursday. The consensus is "hold", but the practical message from the active names is that the bull case remains intact, just with a tighter margin. Even at $62, the cluster of targets sits roughly 16% above current levels, a gap that reflects either genuine upside conviction or reluctance to chase the stock lower with an announcement imminent. The bull case rests on 7.2% revenue growth, a 9% rise in net interest income to $15.7 billion, and a 21% year-on-year gain in consumer banking net income. Bears point to a CET1 ratio that dipped to 11.2% and a supplementary leverage ratio that fell 20 basis points to 5.5%, alongside the broader macro risks that hang over any credit-heavy lender.
Factor scores add some texture to the positioning. BAC ranks in the 92nd percentile on analyst recommendation differentiation, meaning its consensus rating compares well against the universe, and the 84th percentile dividend score underlines income-investor support. The earnings-surprise rank at the 65th percentile is decent without being exceptional. Short interest is barely worth discussing at 1.1% of free float, essentially unchanged over the past week, and the borrow market is wide open with availability far in excess of what anyone seeking to build a short position would need. Cost to borrow is 0.48%, up about 9% on the week but still in basis-point territory. Short sellers have no meaningful position in this stock, and there is no squeeze dynamic at work.
Options positioning offers little drama either. The put/call ratio is 1.23, almost exactly in line with its 20-day average of 1.24, with a z-score near zero. That is remarkably calm for a stock down 15% in a month heading into a major print. The 52-week range on the PCR runs from 1.04 to 1.67, so the current reading is firmly in the middle. There is no unusual hedging pressure, no sign that options traders are scrambling to protect against a miss.
Ownership carries one notable data point. Berkshire Hathaway's 13G/A filing from November 2025 showed Warren Buffett at 7.8% of shares, down from 8.9% previously. Current institutional data shows Berkshire at roughly 483 million shares, or 6.9% of the register. BlackRock has been a small net buyer, adding around 6.4 million shares to reach 7.8% of the stock. As always with 13D/G disclosures, positions are as last filed and holders can fall below 5% without a further filing.
The FDIC call-report data tracked by ORTEX Alt Data carries two notable facts heading into next week's release. Net loans and leases at BAC's insured bank charters has risen for nine consecutive quarters, reaching $1.21 trillion in the April 2026 period. Total deposits came in at a record $2.13 trillion in Q2 2026, the largest second quarter on record since 2024. Neither of the alt-data datasets covering BAC has yet accumulated enough history to test whether they lead the company's reported figures, so these are measures of the underlying business, not pointers to the print.
The last two earnings reactions give the setup its clearest frame. The July 2026 print produced a 3.5% gain on the day and a further 2.9% over the following week. Before that, the May 2026 print delivered a flat day and a 5% slide over five sessions. With the stock already down sharply and targets compressed, the October 14 announcement is the next hard test of whether that analyst consensus holds or begins to crack.
See the live data behind this article on ORTEX.
Open BAC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
